Alogliptin and Metformin Fixed-Dose Combination
AssetAlso called Kazano
Fixed-dose combination of DPP-4 inhibitor alogliptin and biguanide metformin.
- Stage
- Approved
- Modality
- Small molecule
- Target
- Not known
- 2
- Indications
- 1
- Trial
- 1
- Developer
Approved by the FDA on Jan 25, 2013 (NDA203414). FDA
Indications
2Type 2 diabetes
Approved, FDA
Diabetes mellitus
Phase 3, Completed, NCT01890122, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.